Nisevokitug

DB17561InvestigationalProtein Based Therapies

Nisevokitug is a monoclonal antibody targeted against transforming growth factor beta (TGFβ) under investigation in NCT04097821 (A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety and Efficacy of Novel...

Mechanism: Pharmacologically active on Transforming growth factor beta-1 proprotein
Curator reviewed
Also known as: Anti-tgf-beta monoclonal antibody nis793
Code names: NIS-793

Resolves to

Compound

UNIIW2OR26S7UECAS2649854-92-0

Targets

P01137TGFB1

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Nisevokitug, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account